Signos Review
Best for: Pairing compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor and app
Signos (Signos+) is a metabolic-health platform that bundles clinician-prescribed compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor (CGM) and app — pairing the medication with real-time glucose data and coaching so users understand and sustain their weight loss. The program starts at $199/mo on a 6-month plan, includes free shipping, and is HSA/FSA eligible. It is pitched as the same price as medication alone, with the CGM added.
Medium confidence · Last verified 2026-06-04 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Signos is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Signos prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| 6-month program | compounded | $199 |
✓ Pros
- •Bundles compounded GLP-1 (semaglutide) with an FDA-cleared CGM and app — glucose-guided weight loss, not just medication
- •Starting at $199/mo on a 6-month program, with the CGM included at no extra cost
- •Free rapid shipping; HSA/FSA eligible
- •Real-time glucose insights and app coaching to help sustain results after GLP-1
✗ Cons
- •Compounded GLP-1s are not FDA-approved finished products
- •Headline price is a 6-month-program rate, not month-to-month
- •Only semaglutide is shown in the program; tirzepatide availability is not confirmed
- •Compounding pharmacy partner and state availability are not published on the landing page
Ready to start with Signos?
Starting at $199/month. See current pricing and start your free consultation.
Sources & methodology
Our Signos review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to Signos
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Signos?
Starting at $199/month. See current pricing and start your free consultation.